• Mutation; HGNC; 11998; TP53; Simple; p.Asp281Glu (c.843C>G); ClinVar=VCV000376587; Zygosity=Hemizygous (PubMed=16434369; DepMap).
  

PubMed=16434369
Zamo A., Ott G., Katzenberger T., Adam P., Parolini C., Scarpa A., Lestani M., Menestrina F., Chilosi M.
Establishment of the MAVER-1 cell line, a model for leukemic and aggressive mantle cell lymphoma.
Haematologica 91:40-47(2006)

PubMed=24362935; DOI=10.1038/nm.3435
Rahal R., Frick M., Romero R., Korn J.M., Kridel R., Chan F.C., Meissner B., Bhang H.-E.C., Ruddy D., Kauffmann A., Farsidjani A., Derti A., Rakiec D., Naylor T., Pfister E., Kovats S., Kim S., Dietze K., Dorken B., Steidl C., Tzankov A., Hummel M., Monahan J., Morrissey M.P., Fritsch C., Sellers W.R., Cooke V.G., Gascoyne R.D., Lenz G., Stegmeier F.
Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma.
Nat. Med. 20:87-92(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25315077; DOI=10.3109/10428194.2014.970548
Fogli L.K., Williams M.E., Connors J.M., Reid Y.A., Brown K., O'Connor O.A.
Development and characterization of a Mantle Cell Lymphoma Cell Bank in the American Type Culture Collection.
Leuk. Lymphoma 56:2114-2122(2015)

PubMed=25688540; DOI=10.1002/cyto.a.22643
Maiga S., Brosseau C., Descamps G., Dousset C., Gomez-Bougie P., Chiron D., Menoret E., Kervoelen C., Vie H., Cesbron A., Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.
A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines.
Cytometry A 87:285-288(2015)

PubMed=27697772; DOI=10.1182/blood-2016-06-720490
Chiron D., Bellanger C., Papin A., Tessoulin B., Dousset C., Maiga S., Moreau A., Esbelin J., Trichet V., Chen-Kiang S., Moreau P., Touzeau C., Le Gouill S., Amiot M., Pellat-Deceunynck C.
Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma.
Blood 128:2808-2818(2016)

PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004
Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H., Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H., Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.
Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.
Clin. Cancer Res. 24:3967-3980(2018)